Ignite Creation Date:
2024-05-06 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06134830
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-06
First Post:
2023-11-13
Brief Title:
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Clinical Outcome and Quality of Life in Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 Determine the frequency of utilizing single and multiple doses of radioactive iodine RAI in treatment of differentiated thyroid cancer
2 Asses the impact of various doses of radioactive iodine on the management of differentiated thyroid cancer
3 Investigate the influence of thyroid cancer on the quality of life of affected patients
2 Asses the impact of various doses of radioactive iodine on the management of differentiated thyroid cancer
3 Investigate the influence of thyroid cancer on the quality of life of affected patients
Detailed Description:
Differentiated thyroid cancer represents more than 90 of cancer thyroid 1 Total thyroidectomy is considered the mainstay of curative therapy with radioactive iodine RAI in order to ablate or treat remnant thyroid tissue in the surgical bed andor elsewhere 2 The two main objectives for treatment of differentiated cancer thyroid are reducing the probability of cancer recurrence and facilitating serological surveillance via thyroglobulin TG The 2015 American Thyroid Association ATA guidelines as well as European Consensus Conference described three main risk stratification for thyroid cancer including low intermediate and high risk 3 4 According to the 2015 ATA guidelines low- dose 1110 MBq 131I ablation is recommended for low-to- intermediate-risk patients while high-dose 3700 MBq or more 131I ablation may be required for high-risk patients to remove microscopic residual disease4 The optimal RAI activity needed to achieve the best objective RAI response and to minimize RAI specific adverse effects is not known since there are many factors that should be considered while determining the dose including age of the patient and many pathological factors 5 6 Therefore dose adjustment might be needed for patients with same risk classification Just following the guidelines might not be optimal for treatment of individual differentiated thyroid cancer 5 Accordingly in our centre the administrated activities are varied among our clinicians In this study we aim to retrospective analyse patients with differentiated thyroid cancer received variable single and multiple doses of RAI in each risk group and to assess their clinical outcome As thyroid cancer has a very good prognosis there a debate that quality of life may be affected in patients with high risk compared to low and intermediate risks Additionally we intend to evaluate the impact of thyroid cancer on quality of life by questionnaire filled by patients with different risk groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None